stoxline Quote Chart Rank Option Currency Glossary
  
Talis Biomedical Corporation (TLIS)
1.665  0 (0%)    02-05 15:00
Open: 1.665
High: 1.665
Volume: 200
  
Pre. Close: 1.665
Low: 1.665
Market Cap: 3(M)
Technical analysis
2025-02-06 10:51:37 AM
Short term     
Mid term     
Targets 6-month :  2.21 1-year :  2.59
Resists First :  1.89 Second :  2.21
Pivot price 1.63
Supports First :  1.59 Second :  1.39
MAs MA(5) :  1.63 MA(20) :  1.66
MA(100) :  1.74 MA(250) :  5.4
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  51.9 D(3) :  47
RSI RSI(14): 49.4
52-week High :  9.6 Low :  1.37
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TLIS ] has closed below upper band by 43.1%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.67 - 1.67 1.67 - 1.68
Low: 1.65 - 1.66 1.66 - 1.66
Close: 1.65 - 1.67 1.67 - 1.68
Company Description

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Headline News

Thu, 10 Oct 2024
Baker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical Corp - Yahoo Finance

Mon, 09 Sep 2024
Talis Biomedical executive buys $44,240 in company stock - Investing.com

Tue, 03 Sep 2024
Talis Biomedical agrees to $32.5 million settlement - Investing.com

Mon, 26 Aug 2024
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga

Mon, 07 Aug 2023
Chemical spill prompts hazmat response, evacuation at Redwood Shores biomedical firm - CBS San Francisco

Mon, 28 Feb 2022
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Talis Biomedical Corporation (TLIS) Investors - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 765110 (%)
Held by Institutions 8.3 (%)
Shares Short 14 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.558e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -11 %
Return on Assets (ttm) 360.2 %
Return on Equity (ttm) -29.6 %
Qtrly Rev. Growth 408000 %
Gross Profit (p.s.) 0
Sales Per Share -45.18
EBITDA (p.s.) -1.28782e+007
Qtrly Earnings Growth -28.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 0.09
Stock Dividends
Dividend 0
Forward Dividend 17960
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android